Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript Summary
Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript Summary
Under the 12-Point Plan, significant operational improvements have been noted, particularly in the U.S. Recon business which has grown due to improved product supply and commercial execution.The following is a summary of the Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript:
以下是 Smith & Nephew Plc (SNN) 2024 年第三季度业绩电话会议记录摘要：
Financial Performance:
财务业绩：
Smith & Nephew reported Q3 revenue of $1.4 billion, marking a 4% underlying growth.
Projected annual underlying revenue growth revised to 4.5%, with an anticipated trading margin expansion of up to 50 basis points.
Smith & Nephew报告称，第三季度收入为14亿美元，基础增长4％。
预计的年度基础收入增长上调至4.5％，预计交易利润率将增长多达50个基点。
Business Progress:
业务进展：
Under the 12-Point Plan, significant operational improvements have been noted, particularly in the U.S. Recon business which has grown due to improved product supply and commercial execution.
Implementation of robotics and innovation in orthopedics, such as the new CATALYSTEM in hips and advancements in the EVOS plating system, are enhancing Smith & Nephew's product portfolio.
Advanced Wound Management experienced its best growth quarter, driven by increased adoption across regions and categories.
根据12点计划，已注意到显著的运营改善，特别是在美国侦察业务中，由于产品供应和商业执行的改善，该业务有所增长。
机器人的实施和骨科创新，例如臀部的新CatalyStem和EVOS电镀系统的进步，正在增强Smith & Nephew的产品组合。
受各地区和类别采用率上升的推动，高级伤口管理经历了最佳的增长季度。
Opportunities:
机会：
Growth momentum in established markets expected to continue with operational improvements and product innovations.
Advanced robotics and innovative products like CATALYSTEM hip systems and the EVOS plating system represent key growth drivers.
随着运营改善和产品创新，成熟市场的增长势头预计将继续。
先进的机器人和创新产品，例如Catalystem hip系统和EVOS电镀系统，是关键的增长动力。
Risks:
风险：
Projected slower growth from the Sports Medicine Volume-Based Procurement (VBP) in China, along with delayed benefits from expected volume increases, likely contributing more to margin pressure in 2025.
Persistent underperformance and low order expectations in China's recon business impacting near-term growth prospects.
预计中国运动医学批量采购（VBP）的增长将放缓，加上预期销量增长带来的延迟收益，可能进一步加剧2025年的利润压力。
中国侦查业务持续表现不佳，订单预期低，影响了短期增长前景。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
小贴士：本文由 AI 生成。无法完全保证内容的准确性。如需更全面的详情，请访问投资者关系网站。本文仅供投资者参考，不提供任何指导或建议建议。
